Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas

  • Choi, Tae Won (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Kim, Hyo-Cheol (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Lee, Jeong-Hoon (Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Yu, Su Jong (Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Kang, Beomsik (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Hur, Saebeom (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Lee, Myungsu (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Jae, Hwan Jun (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Chung, Jin Wook (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital)
  • Received : 2015.04.27
  • Accepted : 2015.07.11
  • Published : 2015.11.01
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the safety and clinical outcomes of chemoembolization in Child-Pugh class C patients with hepatocellular carcinomas (HCC). Materials and Methods: The study comprised 55 patients with HCC who were classified as Child-Pugh class C and who underwent initial chemoembolization between January 2003 and December 2012. Selective chemoembolization was performed in all technically feasible cases to minimize procedure-related complications. All adverse events within 30 days were recorded using the Common Terminology Criteria for Adverse Events (CTCAE). The tumor response to chemoembolization was evaluated using the modified Response Evaluation Criteria In Solid Tumors. Results: Thirty (54.5%) patients were within the Milan criteria, and 25 (45.5%) were beyond. The mortality of study subjects at 30 days was 5.5%. Major complications were observed in five (9.1%) patients who were all beyond the Milan criteria: two hepatic failures, one hepatic encephalopathy, and two CTCAE grade 3 increases in aspartate aminotransferase/alanine aminotransferase abnormality. The mean length of hospitalization was $6.3{\pm}8.3days$ (standard deviation), and 18 (32.7%) patients were discharged on the next day after chemoembolization. The tumor responses of the patients who met the Milan criteria were significantly higher (p = 0.014) than those of the patients who did not. The overall median survival was 7.1 months (95% confidence interval: 4.4-9.8 months). Conclusion: Even in patients with Child-Pugh class C, chemoembolization can be performed safely with a selective technique in selected cases with a small tumor burden.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74 https://doi.org/10.1055/s-0030-1247133
  2. Hwang S, Lee SG, Belghiti J. Liver transplantation for HCC: its role: Eastern and Western perspectives. J Hepatobiliary Pancreat Sci 2010;17:443-448 https://doi.org/10.1007/s00534-009-0241-0
  3. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
  4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
  5. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188 https://doi.org/10.1053/j.gastro.2004.04.006
  6. Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, et al. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 2011;33:1160-1170 https://doi.org/10.1002/jmri.22542
  7. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007;18:365-376 https://doi.org/10.1016/j.jvir.2006.12.004
  8. Kim HC, Chung JW, Jae HJ, Yoon JH, Lee JH, Kim YJ, et al. Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology 2010;257:278-287 https://doi.org/10.1148/radiol.10100105
  9. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  10. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699 https://doi.org/10.1056/NEJM199603143341104
  11. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/. Accessed June 14, 2010
  12. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001;12:321-326 https://doi.org/10.1016/S1051-0443(07)61911-3
  13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60 https://doi.org/10.1055/s-0030-1247132
  14. Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2012;23:287-294 https://doi.org/10.1016/j.jvir.2011.11.029
  15. Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007;18:1517-1526; quiz 1527 https://doi.org/10.1016/j.jvir.2007.07.035
  16. Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 2006;17:47-53 https://doi.org/10.1097/01.RVI.0000195074.43474.2F
  17. Dhanasekaran R, Khanna V, Kooby DA, Spivey JR, Parekh S, Knechtle SJ, et al. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:1197-1204; quiz 1204 https://doi.org/10.1016/j.jvir.2010.04.018
  18. Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000;215:123-128 https://doi.org/10.1148/radiology.215.1.r00ap21123
  19. Miyoshi S, Minami Y, Kawata S, Imai Y, Saitoh R, Noda S, et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. Assessment by maximal removal rate of indocyanine green. J Hepatol 1988;6:332-336 https://doi.org/10.1016/S0168-8278(88)80050-3
  20. Khan KN, Nakata K, Kusumoto Y, Shima M, Ishii N, Koji T, et al. Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma. Cancer Res 1991;51:5667-5671
  21. Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009;39:374-381 https://doi.org/10.1111/j.1872-034X.2008.00465.x
  22. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol 2009;32:255-264 https://doi.org/10.1007/s00270-008-9468-4
  23. Choi WS, Kim HC, Hur S, Choi JW, Lee JH, Yu SJ, et al. Role of C-arm CT in identifying caudate arteries supplying hepatocellular carcinoma. J Vasc Interv Radiol 2014;25:1380-1388 https://doi.org/10.1016/j.jvir.2014.02.028
  24. Lee IJ, Chung JW, Yin YH, Kim HC, Kim YI, Jae HJ, et al. Cone-beam CT hepatic arteriography in chemoembolization for hepatocellular carcinoma: angiographic image quality and its determining factors. J Vasc Interv Radiol 2014;25:1369-1379; quiz 1379-1379.e1 https://doi.org/10.1016/j.jvir.2014.04.011
  25. Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992;163:387-394 https://doi.org/10.1016/0002-9610(92)90039-T

Cited by

  1. Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators vol.22, pp.22, 2016, https://doi.org/10.3748/wjg.v22.i22.5276
  2. Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory? vol.28, pp.4, 2015, https://doi.org/10.1007/s00330-017-5110-7
  3. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma vol.28, pp.5, 2018, https://doi.org/10.1007/s00330-017-5145-9
  4. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodu vol.19, pp.2, 2018, https://doi.org/10.3348/kjr.2018.19.2.237
  5. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization vol.41, pp.12, 2018, https://doi.org/10.1007/s00270-018-2023-z